The Wilms tumor antigen (WT1) is a zinc-finger transcription factor and is expressed during normal ontogenesis. Expression is absent or restricted to a very low level in adult healthy tissue. However, WT1 is expressed at high levels in various types of leukemia and solid tumors, including lung, breast, colon cancer and soft tissue sarcomas. The WT1 protein is highly immunogenic and has become an attractive target for anticancer immunotherapy.
Spontaneous humoral and cellular immune responses against WT1 have been described in patients with leukemia. Therefore WT1 has become an attractive target for tumor-directed immunotherapy.
The in vitro
stimulation of WT1-specific CD4+
T cells with MACS GMP PepTivator WT1 causes them to produce the effector cytokine IFN-gamma. The presence of IFN-gamma on the cell surface then permits the enrichment of WT1-specific effector/memory T cells with the use of the CliniMACS Cytokine Capture System (IFN-gamma).
Adoptive transfer of WT1-specific T cells or vaccination with WT1-pulsed dendritic cells may be an effective tool for the treatment of WT-expressing malignancies.
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.